562 results about "Drug effect" patented technology

The invention discloses a sewage denitrification dosing method and system based on machine learning and a storage medium, and belongs to the technical field of sewage treatment.The method includes the steps that data are collected and preprocessed, and variable data influencing biochemical pool carbon source dosing behaviors are obtained; and lagging influence of carbon source input on the denitrification amount index is analyzed, and the duration time range of the drug effect is determined. And adopting the trained prediction model, and based on the denitrification amount index and the prediction variable of the future t + X period, obtaining the dosage of the (t + 1) th period. Through a correlation analysis method, the correlation rule of nitrogen conversion in the future X period after the carbon source is added is analyzed, the duration time of the drug effect is determined, the lag effect is accurately quantified, and the problem of mismatching of regulation and control opportunities is avoided. The hysteresis effect is captured and subjected to multi-factor coupling analysis based on the prediction model, the carbon source adding amount and time are optimized, system load fluctuation caused by excessive carbon sources or incomplete nitrogen removal caused by insufficient carbon sources are avoided, and the stability of an original sewage ecological system is gradually improved.

The invention discloses a ginsenoside liposome. The ginsenoside liposome comprises ginsenoside, phospholipid and a surfactant, and the ginsenoside comprises protopanoxadiol or / and protopanaxatriol. The invention also discloses a preparation method of the ginsenoside liposome and application of the ginsenoside liposome in preparation of medicines, cosmetics or skin care products. According to the invention, the final desugared product of ginsenoside with the effect of treating skin toxicity reaction is prepared into the liposome, so that the membrane permeation and absorption capabilities of ginsenoside are greatly improved, the skin toxicity caused by tumor treatment can be quickly and effectively relieved, and the drug effect can be played for a long time; the invention provides a new method for treating skin toxic reaction caused by tumor treatment, and makes up for the requirements which cannot be met by the existing treatment means.

The invention relates to a painless gastrointestinal endoscope self-adaptive drug delivery method and system based on multi-source physiological signal fusion, and belongs to the technical field of medical artificial intelligence and automatic control. An artificial intelligence model is utilized to deeply extract features and quantitatively evaluate the sedation-analgesia level of a patient, a pharmacokinetics-pharmacodynamics model constructed by a big data platform is utilized to dynamically predict the drug effect according to the individual features and real-time state of the patient, and the anesthetic infusion rate is automatically and accurately adjusted through a closed-loop control algorithm, so that the patient can be accurately infused. Personalization and self-adaption of drug delivery are achieved, an independent safety monitoring mechanism is set, and real-time intervention is conducted on risk events such as respiratory depression. The problems that traditional anesthesia depends on artificial experience, single parameter monitoring is not comprehensive and individualized dynamic adjustment is lacked can be effectively solved, and the safety, comfort and medical efficiency of painless gastrointestinal endoscopy are remarkably improved.

The invention relates to the technical field of pharmaceutical knowledge maps, in particular to a pharmaceutical knowledge map construction method and system based on artificial intelligence, and the method comprises the following steps: querying and collecting a molecular structure of a drug and a corresponding target protein sequence through a database, and carrying out the numerical coding of the molecular structure data of the drug, molecular fingerprints and protein structural domain features are extracted, and a drug and protein feature set is formed by combining drug chemical attributes and protein sequence features. According to the invention, through accurate analysis of the molecular structure of the drug and the target protein sequence thereof, the innovative scheme significantly enhances the understanding of the interaction of the drug and the protein, so that researchers can directly extract key features from data and monitor the dynamic change of the drug effect, thereby not only accelerating the development process of the drug, but also improving the development efficiency of the drug. By dynamically tracking the interaction between the side effect of the medicine and the pathological characteristics, the scheme provides powerful data support for personalized medical treatment.

The invention relates to the technical field of intelligent anesthesia precise regulation and control, and discloses an anesthetic dosage optimization method based on artificial intelligence. According to the method, a dynamic treatment interval is constructed, and the boundary of the dynamic treatment interval is adaptively adjusted according to the real-time sedation depth and the nociceptive stimulation level. And in the interval, performing pattern recognition on the continuous electroencephalogram signals and the hemodynamic parameters, and marking abnormal events deviating from a standard anesthesia state. And establishing a correlation network of the drug effect chamber concentration and the abnormal events, and generating a virtual drug response curve for predicting the trend of the abnormal events under different doses. Whether dose strategy reconstruction is started or not is determined by comparing the goodness of fit between the prediction curve and the actual physiological trajectory. During reconstruction, contribution weights of historical drug infusion points to abnormal events are backtracked and analyzed, and adjustment coefficients are distributed and integrated into a new infusion sequence. According to the invention, individualization and self-adaptive optimization of anesthesia administration are realized, and the accuracy and safety of anesthesia depth control are improved.

The invention provides an asymmetric drug interaction prediction method based on a diffusion diagram attention network, and relates to the technical field of drug interaction prediction.The method comprises the steps that a directed graph network is constructed by using chemical structure features of drug molecules, and features are extracted from drug applying and receiving perspectives through a two-way diagram attention network; therefore, the asymmetry between the drugs is effectively represented. Furthermore, a diffusion model is introduced to carry out noise injection and de-noising processing on a graph structure, so that the adaptability of the model to sparse data and the robustness of feature extraction are remarkably enhanced. Finally, multi-modal features are fused through a deep neural network, and high-precision prediction of drug interaction is realized. Compared with the prior art, the method has the advantages that the prediction accuracy exceeds that of the prior art, the dependence on labeled data is greatly reduced, the feasibility and generalization ability of the model in practical application are greatly improved, and a new technical path is provided for safety evaluation and precise medical research of drug combination therapy.

The invention provides a whole-process targeting polypeptide, a drug compound thereof, a drug delivery system and application of the whole-process targeting polypeptide. The whole-process targeting polypeptide comprises pHA and VAP which are covalently connected through a bridging structure; the VAP is LVAP, a reverse sequence polypeptide of the LVAP, DVAP or SVAP; wherein the amino acid sequence of the LVAP is as shown in SEQ ID NO: 1; the SVAP is a D-configuration polypeptide of the LVAP; the DVAP is a D-configuration polypeptide of the LVAP inverted sequence polypeptide; the bridging structure is amino-monoethylene glycol-carboxylic acid or a derivative thereof. The whole-process targeting polypeptide not only can cross a blood-brain barrier, target tumor neovascularization, cross a blood-tumor barrier, target tumor mimicry vessels, tumor cells and stem cells thereof, but also has better tumor cell affinity, anti-tumor treatment and in-vivo safety effects. Meanwhile, the drug compound or the drug delivery system has a synergistic effect after being combined with a chemotherapeutic drug, and the anti-tumor drug effect can be remarkably improved.

The invention relates to a deep learning method-based pharmacokinetics-pharmacodynamics and reinforcement learning-based propofol administration method and application thereof, a PKPD model is used for simulating the metabolic process of propofol in a human body, and a time dependency relationship and dynamics continuous information are extracted through LSTM and Neural OED; then a nonlinear relation between the propofol drug effect concentration and a clinically observed anesthesia depth index BIS is established through a Kan network, mapping between monitoring information and the anesthesia depth in an operation is rapidly established, a strategy is adjusted in time according to environment changes, and the method is suitable for processing non-standardized complex problems and has good application prospects. And the dosage and the administration scheme of the medicine are individually adjusted, so that the treatment effect is improved.

The invention provides a dynamic medication dosage optimization method fused with reinforcement learning. The method comprises the following steps: acquiring a first physiological index parameter of a target patient; obtaining a first diagnosis report of the target patient, wherein the first diagnosis report comprises basic information of the target patient and first disease information of the target patient; the first disease information comprises a first disease type and first disease description information; determining a first reinforcement learning algorithm corresponding to the first disease type; determining a first control parameter of the first reinforcement learning algorithm according to the first physiological index parameter and the basic information; and performing operation on the first disease description information through the first reinforcement learning algorithm and the first control parameter to obtain a first medication dosage parameter. Based on the application, the drug effect can be consistent with the physical condition of a patient, and poor drug effect and excessive side effects caused by too strong drug effect are avoided.

The invention relates to the technical field of traditional Chinese medicine research, in particular to a discovery method of a cough relieving and phlegm eliminating quality marker of cough relieving granules and the quality marker. According to the application, the cough-relieving and phlegm-eliminating drug effects of the cough-relieving granules are evaluated by virtue of concentrated ammonia water cough inducing and phenol red excretion tests, plasma pharmaceutical chemistry research of the cough-relieving granules is developed by virtue of a UHPLC-Q-Exactive Plus Orbitrap HRMS technology, and 26 prototype blood-entering components of the cough-relieving granules are analyzed and identified; through network pharmacological analysis of components entering blood, 11 potential active components for relieving cough and eliminating phlegm of the cough-relieving granules are screened, relate to 40 common targets such as IL6, TLR4, STAT3 and the like, and mainly participate in signal channels such as PI3K-Akt, HIF-1, EGFR (epidermal growth factor receptor) and the like; the seven prototype blood-entering components are quantitatively analyzed by utilizing pharmacokinetics. The three compounds of azelaic acid, caffeic acid and vanillin are used as the cough relieving and phlegm eliminating quality markers of the cough relieving granules through effectiveness, transitivity and testability. The research result is of great significance in deeply defining the pharmacodynamic material basis of the cough-relieving granules, optimizing the quality standard and promoting the clinical application of the cough-relieving granules.

The invention discloses a novel PARP / CK2 double-target kinase inhibitor small molecule as well as a pharmaceutical composition and application thereof, the small molecule takes benzofuran pyrimidone as a parent drug effect ring and a benzene ring as a connector in drug design, and is coupled with a 1-amino-2-methylisothiourea group, so that the novel PARP / CK2 double-target kinase inhibitor is obtained. The compound has good inhibitory activity on exogenous PARP enzyme, exogenous CK2 alpha enzyme and proliferation activity of various cancer cells, and can be used for preparing antitumor drugs. # imgabs0 #

Compared with the prior art, the traditional Chinese medicine compound oral liquid is mainly used for invigorating qi and blood, regulating yin and yang, nourishing liver and kidney, strengthening spleen and stomach, strengthening muscles and bones and the like, a plurality of traditional Chinese medicine components are compounded and decocted to obtain liquid medicine, and finally specific modified polysaccharide, steviosin, sodium benzoate and ethylparaben are added, so that the traditional Chinese medicine compound oral liquid is prepared. The modified polysaccharide is screened and optimized and is added into the compound oral liquid, and the problems of serious wall hanging and high liquid medicine waste rate in the prior art are solved by reducing the low-temperature storage wall hanging rate and the hydrolysis rate in storage stability on the premise of not influencing the medicine effect and safety.

The invention discloses a medicinal and edible composition relaxing cream and a preparation method thereof. Comprising the following raw materials in parts by weight: 8-12 parts of kelp, 10-15 parts of oysters, 6-10 parts of fingered citron, 5-8 parts of dandelions, 5-8 parts of peach kernels, 10-15 parts of malt, 3-6 parts of brassica juncea, 10-15 parts of poria cocos, 5-8 parts of platycodon grandiflorum, 5-8 parts of fructus gardeniae, 8-12 parts of pericarpium citri reticulatae, 3-6 parts of rhizoma zingiberis, 10-15 parts of mulberries, 10-15 parts of rhizoma polygonati, 8-12 parts of codonopsis pilosula, 10-15 parts of hawthorn fruits, 3-6 parts of cinnamon, 5-8 parts of angelica sinensis and 3-6 parts of radix angelicae. The traditional Chinese medicine composition disclosed by the invention has the advantage of good use effect, and solves the problems that in the use process of the existing composition-relaxing cream, the multi-target synergistic effect is lacked, the curative effect is limited, heat-sensitive components are easy to degrade after long-time high-temperature boiling, and the drug effect exertion is influenced.

The present disclosure relates to siRNA for inhibiting hepatitis B virus and uses thereof. In particular to an oligonucleotide for inhibiting HBV or a pharmaceutically acceptable salt thereof, the oligonucleotide comprises an antisense strand, the antisense strand comprises at least one modified nucleotide, and the nucleotide sequence of the antisense strand comprises a sequence or fragment as shown in any one of SEQ ID NO: 3-35. According to the present invention, the siRNA provides significant inhibition effects for HBsAg, HBV DNA and HBeAg generated by cccDNA and host genome integrated HBV DNA in vivo and in vitro, the drug effect is lasting, and compared with the original sequence, the optimized sequence improves the inhibition effect and the drug effect period, and reduces the off-target toxicity;

The invention provides a compound nystatin ointment and a preparation method thereof, and relates to the technical field of medicine preparation, the compound nystatin ointment comprises active ingredients of nystatin, neomycin sulfate, triamcinolone acetonide and permethrin, and the formula comprises liquid paraffin, white vaseline, wool fat, hexadecanol, PEG-30 dipolyhydroxystearate and glyceryl monoisostearate. According to the compound nystatin ointment preparation prescription process disclosed by the invention, the phenomenon of ointment matrix layering in the use process of commercially available products is mainly solved. According to a pharmaceutical research test, the stability of the compound nystatin ointment is superior to that of a commercially available original development agent, the ointment body character and the stability of active ingredients can be kept under the conditions of high temperature, high humidity, low temperature, freeze thawing and illumination, the maximum single impurity content and the total impurity content in the product are not obviously increased, and the quality is controllable. And meanwhile, an in-vitro transdermal test (IVPT) accidentally finds that the retention amount of related active ingredients is higher than that of the original development agent, and the drug effect is obviously improved. Through clinical test research, the compound nystatin ointment disclosed by the invention can be used for effectively treating external otitis caused by bacteria sensitive to neomycin, fungi sensitive to nystatin and ear mites sensitive to permethrin of dogs and cats.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to nitrogen hydrochloride # imgabs0 # stine eye drops and a preparation process thereof, the nitrogen hydrochloride # imgabs0 # stine eye drops comprise 0.05% of nitrogen hydrochloride # imgabs1 # stine, 0.2-0.3% of hydroxypropyl methylcellulose, 0.1-0.2% of edetate disodium, 0.12-0.15% of an isoosmotic adjusting agent, 0.04-0.07% of a preservative and 0.005-0.0075% of choline aromatic folic acid; the nitrogen hydrochloride # imgabs2 # stine eye drops prepared by the preparation method disclosed by the invention have the advantages that the adsorption of nitrogen hydrochloride # imgabs3 # stine on a low-density polyethylene bottle is well inhibited under the condition of visible light, and the reduction of the concentration of nitrogen hydrochloride # imgabs4 # stine in the eye drops is remarkably prevented, so that the medication safety is improved. Besides, the added cholinofolic acid and hydroxypropyl methylcellulose have small irritation to eyes under a specific ratio, and can also have a large enough contact angle with the eyes of rabbits at high temperature, so that the retention property of the eye drops on the eyes can be improved, and the drug effect can be favorably exerted.

The invention relates to an anti-inflammatory and analgesic external composition, a preparation method and application thereof and a gel preparation, and belongs to the technical field of external pharmaceutical compositions.The anti-inflammatory and analgesic external composition is prepared from, by weight, 3-8 parts of loxoprofen sodium, 500-1000 parts of fried semen brassicae, 300-500 parts of fructus arctii and 10-30 parts of liquorice. The semen brassicae is warm in nature and pungent in taste, belongs to the lung channel, and has the effects of benefiting qi and removing stasis; the fructus arctii is cold in nature, pungent and bitter in taste, belongs to lung and stomach channels and has the effects of detoxifying and promoting eruption, the fructus arctii and the fructus arctii are cold in nature and warm in nature, mutual in medicine property, pungent and divergent in taste and have the effect of transdermal enhancement of the medicine effect, the liquorice is neutral in nature and sweet in taste, belongs to the heart, lung, spleen and stomach channels and has the effects of relieving spasm and pain and harmonizing all the medicines, and the liquorice, the fructus arctii and the liquorice can synergistically play the effects of stimulating menstrual flow and relieving pain. And with the cooperation of loxoprofen sodium, the synergistic interaction effect is achieved in the aspects of diminishing inflammation and relieving pain.

The utility model discloses an injection medicine bottle and an injection assembly, and relates to the technical field of medicine storage devices, the injection medicine bottle comprises a bottle body, the top of the bottle body is provided with a needle seat, the bottle body is internally provided with medicine cavities which are arranged up and down, the medicine cavity at the bottom is filled with first medicine, and the medicine cavity at the top is filled with second medicine. A partition plate is connected to the inner wall of the bottle body in an up-down sliding mode, a vertically-through through hole is formed in the partition plate, and a valve plate is arranged at the top of the through hole. According to the injection medicine bottle and the injection assembly, cross contamination between different kinds of medicine can be reduced, it is ensured that the medicine is still in the optimal state during use, and when the medicine bottle and the injection assembly are communicated, the injection medicine bottle and the injection assembly can adapt to mixing of medicine in different forms, such as mixing of liquid medicine and liquid medicine or mixing of liquid medicine and powder medicine; and the two medicaments can react in time, so that the mixing speed is increased, and the drug effect is improved.

The invention provides a betahistine hydrochloride pharmaceutical preparation and a preparation method thereof. The betahistine hydrochloride pharmaceutical preparation comprises conjugated linoleic acid, betahistine hydrochloride and auxiliary materials. Conjugated linoleic acid and betahistine hydrochloride are combined together for the first time, and conjugated double bonds of conjugated linoleic acid can be specifically combined with nitrite to block the generation of nitrosamine, so that the content of N-nitrosobetahistine can be remarkably reduced. Based on the chemical characteristics of conjugated linoleic acid, conjugated linoleic acid is used as a functional additive, targeted removal of nitrosamine impurities is achieved, and meanwhile the situation that exogenous toxic substances are introduced to affect the drug effect of betahistine hydrochloride is avoided. In the experiment process, it is also accidentally found that after the conjugated linoleic acid is added, the positive effect on cerebrovascular diseases is also achieved.

The invention discloses a drug effect prediction method for drug research and development, and relates to the technical field of drug effect analysis, and the method comprises the steps: collecting drug and target data from a plurality of data sources, and carrying out the preprocessing of the drug and target data; and carrying out feature analysis on the basis of the preprocessed drug and target data to obtain a comprehensive feature sequence, carrying out gene and pathway analysis on a disease applied by the drug, carrying out disease feature coding, and then modeling a disease background. According to the method, drug-target pairs with potential drug effects can be rapidly screened in the early stage of drug research and development through drug effect prediction, further research on a large number of invalid compounds is avoided, time and resources are saved, and then, the interaction strength between the drug and the target is predicted through the model, so that the drug effect is improved. And comprehensive analysis is carried out in combination with a disease background, so that potential drug candidate molecules can be identified more accurately, and the research and development cycle is further shortened.

The invention discloses bee venom-containing skin essence with small irritation and a preparation method of the bee venom-containing skin essence. The skin essence is prepared from PLGA-PEG / liposome nanoparticles, a temperature-sensitive gel matrix, a protective agent, an antioxidant, a stabilizer and ultrapure water, the preparation method comprises the following steps: preparing the PLGA-PEG / liposome nanoparticles, preparing a poloxamer 407 solution, resuspending the nanoparticles, filling and storing. According to the invention, the melittin and the snake venom-like peptide have a synergistic effect on skin wrinkle resistance, so that the skin care effect is improved; pLGA-PEG / liposome nanoparticles are matched with a poloxamer solution to construct a dual sustained-release drug system, so that the irritation of drugs to skin is reduced, the lasting effect of the drug effect is improved, and the obtained skin essence has excellent moisturizing, whitening, anti-wrinkle and antioxidant capacities and is small in irritation.

The invention discloses a detection method for rapid real-time drug effect evaluation and application of the detection method. The detection method comprises the following steps: providing a quantitative corresponding relation between a same-generation calibration change value of electrical characteristics caused by physiological changes such as cell same-representative characteristics and the like and the cell proliferation ability; adhering to-be-detected cells to the surface of the same membrane electrode; applying the medicine to be detected, and observing the same generation measurement change value of the electrical characteristics in a cell proliferation cycle; and based on the quantitative corresponding relationship, obtaining the drug effect of the corresponding real-time proliferation characteristic evaluation drug. According to the detection method provided by the invention, the physiological changes such as the same-representative characteristics of the adherent cells are monitored through the membrane electrode, and after the quantitative corresponding relation between the change indexes of the same-representative characteristics of the cells and the proliferation capacity of the cells is established, the cell proliferation capacity is detected; the change of the cell proliferation capacity can be predicted through physiological changes such as the same representative characteristics of the cells before proliferation and apoptosis of the cells, so that the judgment period of the influence of the medicine on the cells can be greatly shortened, and the progress of medicine evaluation and research and development can be remarkably accelerated.

The invention belongs to the field of biological medicine, and particularly relates to an organic molecule self-assembly serving as a material-free medicine carrying system and a preparation method and application thereof. The invention provides a self-assembly body, the self-assembly body is composed of steroid series molecules, and a material-free drug loading system formed by self-assembly of the steroid series molecules is prepared by optimizing the molecular structure and critical aggregation concentration of the steroids. The material-free drug loading system can be used for loading drugs and preparing drug nano-composites. In the nano compound, the drug effect of the drug is improved, and the effects of reducing toxicity and improving efficiency can be achieved. Furthermore, if the used steroid molecules have biological activity, the pharmacological activity of the steroid molecules is not influenced after the steroid molecules are prepared into the drug nano-composite. The material-free drug loading system prepared by the invention has the advantages of no carrier and two nano preparations taking the traditional material as the carrier, and has a good prospect in the aspect of developing novel nano drug preparations.

The invention provides a diketone biphenyl compound serving as a VAV1 degradation agent and application of the diketone biphenyl compound. Specifically provided are a compound represented by formula (I), a tautomer, a stereoisomer, a pharmaceutically acceptable salt or a prodrug thereof. The compound provided by the invention is good in drug effect and can be used for preparing drugs for treating or preventing VAV1 related diseases.

The invention provides tegorazan D-tartrate and tegorazan phosphate and a preparation method thereof, the tegorazan D-tartrate and the tegorazan phosphate provided by the invention have better dissolving property, meanwhile, the impurity content is slowly increased in a long-term stability test, and excellent water solubility is beneficial to dissolution of a medicine from a pharmaceutical composition, so that the tegorazan D-tartrate and the tegorazan phosphate are suitable for clinical application. The medicine effects including improved bioavailability, maximum blood concentration, peak reaching time and the like can be better exerted. According to the preparation method of the tigorasone new salt, provided by the invention, the use of an organic solvent is reduced, and the problem of organic solvent residue is solved.

The invention discloses a TMPRSS2 protein inhibitor efficacy prediction calculation method. A scoring function is constructed through a logP value, a virtual docking score and living cell inhibitor effect data to predict a drug inhibition effect. The method specifically comprises the following steps: constructing a TMPRSS2 overexpression cell model to screen drugs; the cell viability of various potential inhibitors is detected, and high-toxicity inhibitors are eliminated through a CCK-8 experiment; using flow cytometry to detect the cell average fluorescence intensity through a TMPRSS2 fluorescent probe to evaluate the enzyme activity influence of the inhibitor, and calculating the IC30 value; measuring the logP value of an effective inhibitor, and predicting the binding capacity of the effective inhibitor and TMPRSS2 by using Schrodinger software to obtain a virtual docking score; and analyzing the relationship among the IC30 value, the logP value and the virtual docking score, and constructing a scoring function to predict the drug effect. According to the method, the drug effect prediction can be simply, conveniently and quickly carried out, the drug screening consumption is reduced, and the drug screening period is shortened.

The invention discloses guanfacine hydrochloride sustained-release pellets and a preparation method thereof, and belongs to the technical field of biological medicines. The guanfacine hydrochloride sustained-release pellet comprises a drug-containing pellet core and a sustained-release layer, wherein the sustained-release layer is coated on the outer surface of the drug-containing pellet core; the medicine-containing pill core comprises the following components: guanfacine hydrochloride, a filling agent, a sustained-release material and a lubricating agent; and the sustained-release layer comprises the following components: a retardant, a plasticizer and an anti-sticking agent. The preparation method comprises the following steps: firstly, preparing guanfacine hydrochloride and auxiliary materials into a drug-containing pill core through an extrusion-rolling process, wherein the drug-containing pill core contains part of a sustained-release material for preventing sudden release of a drug; and then coating a sustained-release layer outside the drug-containing pellet core through fluidized bed coating to prepare the guanfacine hydrochloride sustained-release pellet. The guanfacine hydrochloride sustained-release pellet is free of burst release after being taken, is not influenced by individual differences of human bodies and pH of intestinal tracts, can tolerate peristalsis and extrusion of gastrointestinal tracts, is continuously released within 24 hours, keeps a proper concentration level in in-vivo blood, and is beneficial to reducing adverse reactions and continuously exerting drug effects.

The invention relates to the field of medicinal emulsifiable paste, in particular to compound fluconazole emulsifiable paste and a preparation method thereof. The compound fluconazole emulsifiable paste is prepared from the following components in parts by weight: 0.6 to 5 parts of fluconazole, 0.2 to 2 parts of neomycin sulfate, 0.1 to 0.2 part of triamcinolone acetonide, 5 to 15 parts of stearic acid, 10 to 25 parts of white vaseline, 2 to 8 parts of glyceryl monostearate, 0.5 to 3 parts of medicinal dimeticone, 1 to 5 parts of polysorbate-80, 0.1 to 0.3 part of sorbic acid, 0.1 to 1 part of vitamin E, 0.01 to 0.1 part of EDTA (Ethylene Diamine Tetraacetic Acid) disodium, 5 to 15 parts of glycerol and the balance of purified water, wherein the total amount is 100 parts. According to the application, the antioxidant property of the cream is improved by adding the vitamin E and the EDTA disodium, the vitamin E is used for directly scavenging free radicals, the EDTA disodium is used for eliminating an oxidation catalyst, and the quality guarantee period of the cream can be remarkably prolonged and the drug effect can be maintained by combining the vitamin E and the EDTA disodium.

The invention discloses a clinical medical care dispensing and sterilizing device in the technical field of medical care auxiliary equipment, which comprises a sterilizing box, the outer wall of the sterilizing box is fixedly connected with a display controller, the sterilizing box is internally and fixedly connected with a sterilizing assembly and a residue cleaning assembly, and the sterilizing assembly and the residue cleaning assembly are both in signal connection with the display controller. The device is used for solving the problems that traditional manual disinfection and an existing automatic disinfection device have disinfection blind areas and are insufficient in residue treatment when facing dispensing appliances in complex shapes, multi-angle and all-around efficient disinfection of the dispensing appliances is achieved by means of a flexible and movable mechanical structure in a physical and chemical combined disinfection mode, and the dispensing appliances are disinfected more efficiently. And the disinfection blind area is obviously reduced. Meanwhile, the device is provided with a special component for removing disinfection residues, so that the cleanness and safety of the disinfected appliances are ensured, and potential hazards of disinfection by-products to the drug effect and the health of a patient are avoided.

The invention discloses a traditional Chinese medicine compound screening method based on machine learning, and relates to the technical field of biological medicine.According to the traditional Chinese medicine compound screening method, multi-source traditional Chinese medicine compound spleen tonifying related component data are collected and integrated, a data set containing information such as components, medicine effects and indications is constructed, and follow-up model training is supported; utilizing machine learning to train a compound screening model, identifying drug effect related components, predicting effective parts of traditional Chinese medicinal materials of the components, and revealing contribution of the components to the drug effect; structural characteristics of chemical components are extracted, potential pharmacological effects of the chemical components are analyzed, and drug effect and toxicity analysis is supported; and a pharmacodynamic index set is constructed to evaluate the effect, toxicity and timeliness of the components, and support is provided for pharmacodynamic optimization. Animal experiments are combined to verify the synergistic effect among the components, so that the model prediction accuracy is ensured. The proportion of the compound components is adjusted according to the experimental result to maximize the drug effect and reduce the side effect to meet the requirements of different patients.